Nature of Business (Details) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2020	Sep. 30, 2019	Sep. 30, 2020	Sep. 30, 2019	Dec. 31, 2019	Dec. 31, 2018
Accounting Policies [Abstract]
Contracts from NIH and NIAID, description			The Company is currently developing RiVax® under a NIAID contract of up to $21.2 million over six years, and a one-year NIH grant of $150,000 in support of its SGX942 pediatric program. In addition, the Company has a subcontract of approximately $700,000 from a NIAID grant over five years for its thermostabilization technology, and a DTRA subcontract of approximately $600,000 over three years for SGX943.
Accumulated deficit	$ (187,673,869)		$ (187,673,869)		$ (175,525,612)
Net loss	(1,790,160)	$ (2,720,783)	(12,148,257)	$ (6,483,931)
Cash in operating activities			(7,329,471)	(4,866,288)
Cash and cash equivalents	11,342,794	$ 6,551,793	11,342,794	6,551,793	5,420,708	$ 8,983,717
Net change in cash and cash equivalent			$ 5,922,086
Percentage change in cash and cash equivalent			109.00%
Working capital	7,193,758		$ 7,193,758		$ 1,181,249
Increase in cash and cash equivalents			$ 6,012,509
Increase in working capital, percentage			508.00%
Government contract and grant funding amount	$ 900,000		$ 900,000
Remaining from FBR sales agreement, description			The Company has $20.0 million remaining from the FBR Sales Agreement as of November 09, 2020 under the prospectus supplement filed August 28, 2020, as no sales have been made under the FBR Sales Agreement since July 28, 2020.
Paycheck protection program loan amount			$ 417,830